ScreenerHero

NERV Minerva Neurosciences, Inc.

NAS · US · Healthcare · Biotechnology · minervaneurosciences.com
3.220USD-1.53%Mkt Cap: 153.75M $P/E: —

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap153.75M USD
Enterprise Value160.25M USD
Revenue (TTM)—
Gross Profit-15.54M USD
Net Income (TTM)-293.42M USD
Revenue/Share—
Last Price3.220 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.17
PEG—
EV/EBITDA-5.62
EV/Revenue—
P/S—
P/B-0.76
EPS (TTM)-37.32
EPS (Forward)-0.42
52W Range
2.06211% of range12.46
52W High12.46 USD
52W Low2.062 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE208.47%
ROA-299.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.51M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-5.76%
Net Debt-15.27M USD
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity—
Current Ratio20.14
Quick Ratio19.02
Book Value/Sh-4.52 USD
Cash/Share1.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:8
Split DateJun 21, 2022
Analyst Consensus
Rating—
Target (Mean)10.33 USD
Upside (mean)+220.9%
Target Range7.000 USD – 14.00 USD
7.000+220.9% to mean14.00
# Analysts3
Ownership
Shares Out.47.75M
Float34.30M
Insiders3.26%
Institutions93.32%
Short Interest
Short Ratio10.4d
Short % Float5.31%
Short % Out.5.07%
Shares Short2.42M
Short (prev mo.)1.76M
Technical
SMA 504.145 (-22.3%)
SMA 2005.052 (-36.3%)
Beta-0.12
S&P 52W Chg16.45%
Avg Vol (30d)143.20K
Avg Vol (10d)89.87K
Technical Indicators
RSI (14)34.4
MACD-0.2740
MACD Signal-0.2680
MACD Hist.-0.0060
BB Upper4.229 USD
BB Middle3.581 USD
BB Lower2.933 USD
BB Width36.19%
ATR (14)0.2683 USD
Vol Ratio (20d)1.02x